Japan’s GINKAN Inc has raised a $2.6 million Series A funding round led by MTG Ventures, Inc while South Korean chaebol SK Group has acquired a 25 per cent stake in Vietnam’s Imexpharm Corporation.
Japan’s GINKAN raises $2.6m Series A
Japan’s GINKAN Inc., which manages restaurant discovery platform SynchroLife, has raised $2.6 million in its Series A funding round led by MTG Ventures, according to an announcement.
Other investors participating in the round include giftee, Orient Corporation, Ceres, Sansei Capital Investment, Aucfan, DD Holdings Venture Capital, Mitsubishi UFJ Capital and SLD Entertainment.
GINKAN has now raised $3.7 million in total external funding.
The company plans to use the fresh funding to further develop SynchroLife, to augment restaurant services, and to fund marketing campaigns.
“The sudden appearance of Covid-19 has significantly affected the restaurant industry. As a result, it is no exaggeration to say SynchroLife is the perfect service to solve the restaurant industry issues surrounding the costs of marketing and payment processing. Going forward, our group will work together with GINKAN to connect restaurants with food lovers as we both expand globally,” said MTG Ventures representative director and president Go Fujita.
SynchroLife claims to use AI to offer personalised recommendations. It boasts over 210,000 reviews for over 100,000 restaurants.
SK Group acquires 25% stake in Vietnam’s Imexpharm
South Korean chaebol SK Group has acquired a 25 per cent stake in Vietnamese pharmaceutical firm Imexpharm Corporation as part of its efforts to expand its presence in the Southeast Asian country, according to an announcement.
The group’s investment arm, SK South East Asia Investment Pte Ltd, acquired a 24.9 per cent stake, or 12.32 million shares, in Imexpharm last week.
The deal value was not disclosed but local media reports pegged it at $28.9 million.
Foreign investors own approximately 49 per cent in Imexpharm. Its other major shareholders include VinaCapital (7%), KWE Beteiligungen AG (14.3%), and Vietnam Pharmaceutical JSC, also known as Vinapharm (22.9%).